Asimov
PrivateLast Round
Series B
Jan 5, 2023
Total Funding Raised
$204.7M
Company Overview
Asimov is a biotechnology company that provides mammalian cell engineering software and synthetic biology platforms to accelerate the design and production of biologics and gene therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Asimov Comparables
Compare Asimov with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 64x Bio | 84% | |
| ATUM | 79% | |
| Dyno Therapeutics | 77% |
Asimov Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 5, 2023 | ||||
| Series A | Dec 31, 2019 | ||||
| Seed | Dec 19, 2017 |
Asimov Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B, Seed |
| CPP Investments | Series B |
| Horizons Ventures | Series B, Series A |
| Fidelity Management & Research Company | Series B |
| Lux Capital | Series B |
| Koch Disruptive Technologies | Series B |
| Pillar VC | Seed, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 19, 2026
Launched the RNA Edge System, an AI and synthetic biology platform.
- Mar 17, 2026
Partnered with Score Pharma, Inc. for antibody therapeutics.
Recent news
Latest coverage and updates
- is_developingSep 14, 2026
Asimov, Inc. is developing custom cell line development program for this 4-chain bispecific antibody.
- partners_withSep 14, 2026
Asimov, Inc. partnered with Sidewinder Therapeutics, Inc. on Sep 14th '26.
- partners_withAug 21, 2026
Asimov, Inc. partnered with Kaigene, Inc. on Aug 21st '26.
- partners_withAug 18, 2026
Asimov, Inc. partnered with Kaigene, Inc. on Aug 18th '26.
- is_developingAug 18, 2026
Asimov, Inc. is developing high-titer cell line on Aug 18th '26.
Asimov Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Asimov's valuation, stock price, and market status.
Is Asimov a public or private company?
Asimov is a private company.
What is the current stock price of Asimov?
Asimov is a private company with no public stock price. No recent secondary market data is available.
How much is Asimov worth (valuation)?
Valuation information for Asimov is not publicly available.
Can I buy Asimov stock?
Asimov shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Asimov's last funding round?
Asimov's most recent funding round was Series B on January 5, 2023.
Who are the main investors in Asimov?
Key investors in Asimov include Andreessen Horowitz, CPP Investments, Horizons Ventures.
Will Asimov IPO soon?
No public IPO plans have been announced for Asimov.
How can I track Asimov secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Asimov's secondary market activity and sign up for updates.